Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis

Tatiana Ribeiro, Maxime J Fleury, Enrico Granieri, Massimiliano Castellazzi, Fernanda Martini, Elisa Mazzoni, Pierre Coursaget, Mauro Tognon, Tatiana Ribeiro, Maxime J Fleury, Enrico Granieri, Massimiliano Castellazzi, Fernanda Martini, Elisa Mazzoni, Pierre Coursaget, Mauro Tognon

Abstract

Viral agents seem to be linked to multiple sclerosis (MS). This association is based on evidence of (1) early exposure to viruses and MS onset; (2) increased prevalence of MS disease in specific geographic regions; (3) likelihood of developing MS being more prevalent in high-risk areas; (4) altered immune responses to different viruses. In this study, sera from patients affected by MS and controls, represented by sera from patients with other neurologic diseases, both inflammatory and non-inflammatory, and from healthy donors, were investigated for the presence of antibodies against neurotropic polyomaviruses BKV, JCV and SV40 in their sera. Our study has indicated that the prevalence of BKV antibodies in sera from MS patients is higher than that detected in normal individuals, while levels of antibodies against BKV and JCV are lower in MS patients compared to those of normal subjects.

References

    1. J Med Virol. 2003 Jul;70(3):490-5
    1. Clin Infect Dis. 2002 Nov 1;35(9):1081-7
    1. Arch Dis Child. 1992 Jul;67(7):956-7
    1. J Gen Virol. 2001 Dec;82(Pt 12):3005-3009
    1. Lancet Neurol. 2010 Apr;9(4):425-37
    1. Lancet Neurol. 2006 Oct;5(10):887-94
    1. Int J Cancer. 1995 Jun 9;61(6):756-60
    1. Virology. 2004 Jan 5;318(1):1-9
    1. J Gen Virol. 2003 Jun;84(Pt 6):1499-1504
    1. Adv Virus Res. 1998;50:69-99
    1. Adv Exp Med Biol. 2006;577:319-41
    1. Lancet. 2002 Apr 6;359(9313):1221-31
    1. J Autoimmun. 2005;25 Suppl:74-80
    1. Clin Diagn Lab Immunol. 2003 Mar;10(2):278-85
    1. Curr Opin Neurol. 2007 Jun;20(3):261-8
    1. Lancet Neurol. 2007 Sep;6(9):773-81
    1. J Med Virol. 2003 Sep;71(1):115-23
    1. J Natl Cancer Inst. 1999 Jan 20;91(2):119-34
    1. J Exp Med. 2007 Nov 26;204(12):2899-912
    1. Infect Agent Cancer. 2007 Jul 09;2:13
    1. J Natl Cancer Inst. 2003 Oct 15;95(20):1522-30
    1. J Infect Dis. 2009 Mar 15;199(6):837-46
    1. Br J Cancer. 2005 Nov 28;93(11):1305-6
    1. Oncogene. 2003 Aug 11;22(33):5192-200
    1. J Natl Cancer Inst. 2004 Sep 15;96(18):1368-74

Source: PubMed

3
구독하다